Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | European Journal of Endocrinology |
| Vol/bind | 167 |
| Udgave nummer | 2 |
| Sider (fra-til) | 287-94 |
| Antal sider | 8 |
| ISSN | 0804-4643 |
| DOI | |
| Status | Udgivet - 2012 |
ID: 48605745